Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yupingfeng Powder for Allergic Rhinitis
NCT04976023Phase 2Completed
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of yupingfeng in allergic rhinitis (AR) (2 arms). Primary endpoints: Total Nasal Symptom Score at Week 8 and Rhinoconjunctivitis Quality of Life Questionnaire at Week 8. Started Apr 2022; status: completed.
02
Drugs
yupingfeng
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04976023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976023.